IXHL
Incannex Healthcare Limited
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · AU
$3.27
+0.62%Year over year
Reported trailing growth
- Revenue
- -71.8%
- EBITDA
- -82.0%
- EBIT
- +8.4%
- EPS
- +36.4%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +81.4%
- EPS
- +61.6%
Three-year CAGR
- Revenue
- -52.2%
- EBITDA
- +15.0%
- EBIT
- +20.8%
- Net income
- —
- EPS
- —
- Free cash flow
- +22.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026